Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

Chief Financial Officer

President & CEO

Chief Development Officer

Chief Legal & Compliance Offic

Chief Commercial Officer

Chief Scientific Officer

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-03	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-04-02	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-04-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-04-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2024-04-01	Premium	sold (taxes)	Premium	Premium	Premium	President & CEO
2024-04-01	Premium	sold (taxes)	Premium	Premium	Premium	-
2024-04-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Development Officer
2024-03-31	Premium	acquired	Premium	Premium	Premium	Chief Development Officer
2024-03-31	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-31	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-03-31	Premium	acquired	Premium	Premium	Premium	President & CEO
2024-03-31	Premium	acquired	Premium	Premium	Premium	-
2024-03-28	Premium	sold (taxes)	Premium	Premium	Premium	Chief Legal & Compliance Offic
2024-03-27	Premium	acquired	Premium	Premium	Premium	Chief Legal & Compliance Offic
2023-12-21	Premium	bought	Premium	Premium	Premium	-
2023-12-12	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-12-06	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-11-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-11-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Commercial Officer
2023-11-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2023-11-01	Premium	sold (taxes)	Premium	Premium	Premium	President & CEO
2023-11-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Development Officer
2023-10-31	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-10-31	Premium	acquired	Premium	Premium	Premium	Chief Commercial Officer
2023-10-31	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer

SYRS - Syros Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for SYRS